课题基金 / 基金详情

Characterization and therapeutic implication of a novel class of PKC-theta inhibitors selectively targeting undifferentiated cancer cells expressing stem cell markers

Characterization and therapeutic implication of a novel class of PKC-theta inhibitors selectively targeting undifferentiated cancer cells expressing stem cell markers
选择性靶向表达干细胞标记物的未分化癌细胞的一类新型 PKC-theta 抑制剂的表征和治疗意义
批准号：
443660
负责人：
Alaoui-Jamali Moulay A
金额：
$66.04万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
未结题
起止时间：
2021-04-01 至 2026-04-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=443660&lang=en
关键词：
Cancer Stem Cells Cell Differentiation Genomics Metabolism Mouse Cancer Models Pharmacology Preclinical Cancer Models Small Molecules Undifferentiated/High Grade Cancer

项目摘要

项目成果

Alaoui-Jamali Moulay A的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The primary goal of this project is to reveal the molecular mechanism of a novel class of chemical selectively targeting an enzyme called PKC-theta whose excessive activity is associated with several chronic and incurable diseases, including advanced canc
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Triple Targeted Kinase Inhibitors Capable of Inhibiting Breast Cancer Metastases
Investigation of the Filamin Signaling Network's Function in Cancer Progression
Molecular and Translational Studies of Filamin Signaling Network in Invasive Cancer
Discovery and Validation of Pharmacological Probes for Understanding Protein-Protein Interactions of Focal Adhesion Signalling in Invasive Cancer Cells
海外基金